SG11202005510SA - Therapeutic enzyme fusion protein having a novel structure and use thereof - Google Patents

Therapeutic enzyme fusion protein having a novel structure and use thereof

Info

Publication number
SG11202005510SA
SG11202005510SA SG11202005510SA SG11202005510SA SG11202005510SA SG 11202005510S A SG11202005510S A SG 11202005510SA SG 11202005510S A SG11202005510S A SG 11202005510SA SG 11202005510S A SG11202005510S A SG 11202005510SA SG 11202005510S A SG11202005510S A SG 11202005510SA
Authority
SG
Singapore
Prior art keywords
fusion protein
novel structure
enzyme fusion
therapeutic enzyme
therapeutic
Prior art date
Application number
SG11202005510SA
Other languages
English (en)
Inventor
Eui Joon Jung
Jin Young Kim
In Young Choi
Sung Youb Jung
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of SG11202005510SA publication Critical patent/SG11202005510SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202005510SA 2017-12-22 2018-12-21 Therapeutic enzyme fusion protein having a novel structure and use thereof SG11202005510SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170178378 2017-12-22
PCT/KR2018/016487 WO2019125059A1 (ko) 2017-12-22 2018-12-21 신규한 구조를 갖는 치료학적 효소 융합단백질 및 이의 용도

Publications (1)

Publication Number Publication Date
SG11202005510SA true SG11202005510SA (en) 2020-07-29

Family

ID=66993643

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005510SA SG11202005510SA (en) 2017-12-22 2018-12-21 Therapeutic enzyme fusion protein having a novel structure and use thereof

Country Status (16)

Country Link
US (1) US20210009984A1 (de)
EP (1) EP3708661A4 (de)
JP (1) JP7403455B2 (de)
KR (2) KR102588611B1 (de)
CN (1) CN111511910A (de)
AR (1) AR113430A1 (de)
AU (1) AU2018388331A1 (de)
BR (1) BR112020012346A2 (de)
CA (1) CA3086474A1 (de)
EA (1) EA202091239A1 (de)
IL (1) IL275248A (de)
MX (1) MX2020006635A (de)
PH (1) PH12020550927A1 (de)
SG (1) SG11202005510SA (de)
TW (1) TW201934753A (de)
WO (1) WO2019125059A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111511910A (zh) 2017-12-22 2020-08-07 韩美药品株式会社 具有新颖结构的治疗酶融合蛋白及其用途
EP3895708A3 (de) * 2019-08-07 2022-01-19 Amicus Therapeutics, Inc. Verfahren zur behandlung von morbus fabry bei patienten mit einer mutation in dem gla-gen
EP4229192A1 (de) 2020-10-14 2023-08-23 Denali Therapeutics Inc. Fusionsproteine mit sulfoglucosamin-sulfohydrolase-enzymen und verfahren dafür
CN116419759A (zh) * 2020-11-13 2023-07-11 韩美药品株式会社 治疗酶融合蛋白在预防和治疗由法布里病引起或伴有法布里病的神经病中的用途
KR20220065719A (ko) * 2020-11-13 2022-05-20 한미약품 주식회사 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도
KR20230134822A (ko) * 2022-03-15 2023-09-22 주식회사 녹십자 α-갈락토시다제 A의 융합단백질을 포함하는 액상 제제
KR20230134823A (ko) * 2022-03-15 2023-09-22 주식회사 녹십자 α-갈락토시다제 A의 융합단백질을 포함하는 동결 건조 제제

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69309472T2 (de) 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
HUP0500423A2 (hu) * 1999-09-17 2005-08-29 Gtc Biotherapeutics, Inc. Transzgenikus úton előállított fúziós fehérjék
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2006108586A2 (en) * 2005-04-11 2006-10-19 Sanofi Pasteur Polymyxin b analogs for lps detoxification
ATE509954T1 (de) * 2005-12-30 2011-06-15 Merck Patent Gmbh Anti-cd19-antikörper mit reduzierter immunogenität
CN101687933B (zh) * 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
IL243690B (en) * 2013-07-31 2022-09-01 Amgen Inc Stabilization of polypeptides involving fc
EA035527B1 (ru) 2014-12-30 2020-06-30 Ханми Фарм. Ко., Лтд. Производные глюкагона с улучшенной стабильностью
JP7320944B2 (ja) * 2015-10-08 2023-08-04 マクロジェニクス，インコーポレーテッド Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子
DK3386534T3 (da) * 2015-12-08 2020-11-30 Regeneron Pharma Sammensætninger og fremgangsmåder til internalisering af enzymer
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
IL271837B2 (en) * 2017-07-07 2024-01-01 Hanmi Pharm Ind Co Ltd A new medical fusion protein with an enzyme and its uses
CN111511910A (zh) 2017-12-22 2020-08-07 韩美药品株式会社 具有新颖结构的治疗酶融合蛋白及其用途

Also Published As

Publication number Publication date
IL275248A (en) 2020-07-30
KR20190076909A (ko) 2019-07-02
CA3086474A1 (en) 2019-06-27
KR102588611B1 (ko) 2023-10-16
EA202091239A1 (ru) 2020-09-09
PH12020550927A1 (en) 2021-05-10
NZ765453A (en) 2024-03-22
US20210009984A1 (en) 2021-01-14
KR20230143985A (ko) 2023-10-13
KR102712547B1 (ko) 2024-10-04
JP2021507705A (ja) 2021-02-25
BR112020012346A2 (pt) 2020-11-24
EP3708661A4 (de) 2021-12-01
AR113430A1 (es) 2020-04-29
EP3708661A1 (de) 2020-09-16
TW201934753A (zh) 2019-09-01
CN111511910A (zh) 2020-08-07
AU2018388331A1 (en) 2020-07-02
JP7403455B2 (ja) 2023-12-22
WO2019125059A1 (ko) 2019-06-27
MX2020006635A (es) 2020-12-10

Similar Documents

Publication Publication Date Title
IL275248A (en) Fusion protein of a therapeutic enzyme with a new structure and its use
EP3623389A4 (de) Fusionsprotein mit tgf-rezeptor und dessen medizinische verwendungen
IL267861A (en) PD1-41BBL conjugate protein and methods of using it
IL273439A (en) Conjugated proteins involving enzyme replacement in enzyme therapy
IL267862A (en) SIRPalpha-41BBL conjugate protein and methods of using it
IL280102A (en) Fusion protein containing PD1-4-1BBL and methods of using it
ZA201900209B (en) Novel natural protein and application thereof
ZA202000595B (en) Novel therapeutic enzyme fusion protein and use thereof
EP3722305A4 (de) Hm-3-fusionsprotein und verwendung davon
SG11202104912SA (en) Fusion protein and use thereof
IL280103A (en) Fusion protein containing SIRPalpha-4-1BBL and methods of using it
SG11202110400QA (en) Fusion protein and use thereof
IL290660A (en) Medical protein concentrates
EP3668551A4 (de) Apom-fc-fusionsproteine und verwendung davon
EP3702362A4 (de) Polypeptid mit analgetischer aktivität und verwendung davon
IL272050B1 (en) Synthetic proteins and their therapeutic uses
EP3816181A4 (de) Verbessertes fviii-fusionsprotein und seine verwendung
EP3601572A4 (de) Proteinexpressionskonstrukt und verfahren dafür
ZA201904386B (en) S-arrestin peptides and therapeutic uses thereof
HUP1700012A2 (en) Novel proteins and use thereof
IL292599A (en) tmem219 antibodies and medical uses thereof
EP3875483A4 (de) Fusionsprotein mit ids und seine verwendung
HUE060194T2 (hu) Peptid-származékok és azok terápiai hatása